OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pharmacology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Recent advances in emerging PCOS therapies	117
Corrigendum to “From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling” [COPHAR 76 (2024) 102458]	110
Editorial Board	98
The P2X7 purinoceptor in pathogenesis and treatment of dystrophino- and sarcoglycanopathies	83
Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction	69
Advances in pain therapeutics: Targets, mechanisms, and translational frontiers	52
From “contraindicated” to “first line” – Current mechanistic insights beyond canonical β-receptor signaling	52
Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?	49
Lipid raft disruption as an opportunity for peripheral analgesia	47
The role of extracellular ATP in homeostatic immune cell migration	42
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma	40
Photo-isomerizable tweezers to probe ionotropic receptor mechanisms	38
Optofluidic neural interfaces for in vivo photopharmacology	38
Editorial Board	37
Gastrointestinal issue: Advances in gastrointestinal oncology	35
CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives	34
Editorial overview: Special issue on “Rheumatology: Therapeutic advances for autoimmune and musculoskeletal diseases”	34
Optic nerve regeneration: Potential treatment approaches	34
Pancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis	34
Editorial Board	33
Advanced microneedle arrays for transdermal antibiotic delivery	31
Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus	30
Three-dimensional culture models to study glioblastoma — current trends and future perspectives	29
Pharmaceutical therapies targeting autophagy for the treatment of age-related macular degeneration	29
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance	28

Allogeneic double-negative T-cell therapy for acute myeloid leukemia	28
Current state of CFTR modulators for treatment of Cystic Fibrosis	27
Innovative pipeline therapeutics in IBD: anti-TL1A and bispecific antibodies	27
Paeoniflorin is a promising natural monomer for neurodegenerative diseases via modulation of Ca2+ and ROS homeostasis	27
Editorial Board	25
Animal models of cystic fibrosis in the era of highly effective modulator therapies	25
Editorial Board	24
Therapeutic approaches in different congenital myopathies	23
Targeting TRP channels for pain relief: A review of current evidence from bench to bedside	23
Gene therapies for RyR1-related myopathies	23
Strategies to enhance anti-leukaemia immunotherapy	23
Drug development for the treatment of RyR1-related skeletal muscle diseases	22
Next-gen therapeutics to spare and expand beta-cell mass	22
Editorial overview: An initiative toward Ebolavirus disease (EVD) free world: An edited special anti-infective issue on Ebola virus disease	22
Lipids and lipid regulators in intraocular pressure homeostasis	21
Photopharmacological approaches for dissecting potassium channel physiology	21
Oligonucleotide-based therapies for cystic fibrosis	20
Antihypertensive effect of soybean bioactive peptides: A review	20
Non-alcoholic fatty liver disease: Current therapeutic options	20
The Role of Plant-Derived Compounds in Anti-Obesity Drug Discovery: A Molecular Perspective	20
Smart solutions for tough infections: The rise of next-gen transdermal drug delivery	20
Oncohistone-sculpted epigenetic mechanisms in pediatric brain cancer	20
Nutraceuticals in mental diseases — Bridging the gap between traditional use and modern pharmacology	19
Editorial overview: “Purinergic immune cell regulation reveals novel pharmacological targets”	19
Acupuncture for Depression: Decoding Neuroimmune Crosstalk and Targeting Anti-Inflammatory Mechanisms	19
Photopharmacological control of cell signaling with photoswitchable lipids	19
Shaping DNA damage responses: Therapeutic potential of targeting telomeric proteins and DNA repair factors in cancer	19
Estrogen related receptor alpha: Potential modulator of age-related macular degeneration	19
Purinergic signalling in graft-versus-host disease	18
Antibiotics, the microbiome and gastrointestinal cancers: A causal interference?	18
Challenges in formulating transdermal systems for treating chronic skin infections	18
Functional role of the ER stress transducer IRE1α in CF airway epithelial inflammation	17
Light-activated receptor tyrosine kinases: Designs and applications	17
Targeting fibroblast-like synoviocytes in rheumatoid arthritis	17
Editorial overview: COVID-19 therapy: From lung disease to systemic disorder	17
Role of HSV-1 in Alzheimer's disease pathogenesis: A challenge for novel preventive/therapeutic strategies	17
Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction	17
Highlighting vulnerabilities in the alternative lengthening of telomeres pathway	17
Editorial Board	16
Novel approaches to CAR T cell target identification in acute myeloid leukemia	16
Editorial overview: Introduction to the musculoskeletal section of current opinion in pharmacology	16
Pharmacoutilization data-driven artificial intelligence–assisted diagnosis algorithm to improve the pharmacological treatment of pain and agitation in patients suffering from severe dementia	16
NMR applications to GPCR recognition by peptide ligands	16
Spinal and bulbar muscular atrophy: From molecular pathogenesis to pharmacological intervention targeting skeletal muscle	15
PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?	15
Fluorescent chemigenetic actuators and indicators for use in living animals	15
Revolutionizing UC monitoring: The emerging role of intestinal ultrasound	15
The expanding role of split protein complementation in opsin-free optogenetics	15
CFTR RNA- and DNA-based therapies	15
Novel treatments for dry eye syndrome	15

Advances in tethered photopharmacology for precise optical control of signaling proteins	14
AI-driven GPCR analysis, engineering, and targeting	14
Corrigendum to “Antihypertensive effect of soybean bioactive peptides: A review” [Curr Opin Pharmacol (62) (2022) 74–81]	14
Caffeine consumption and schizophrenia: A highlight on adenosine receptor–independent mechanisms	14
TMEM16A (ANO1) as a therapeutic target in cystic fibrosis	14
Editorial Board	14
Innate and adaptive immune mechanisms regulating central nervous system remyelination	14
Editorial Board	14
Targeting the endocannabinoid system for the management of low back pain	14
Effects of protein glycation and protective mechanisms against glycative stress	14
Immune dysfunction after spinal cord injury – A review of autonomic and neuroendocrine mechanisms	14
Is there still a place for radiotherapy in gastric cancer?	14